MLNT News and Press, Melinta Therapeutics Inc - Ordinary Shares From 01/02/20

Antibiotics maker, Paratek Pharmaceuticals ( PRTK ), has struggled to hold onto gains in 2019. The has been a recent setback in the clinic but success on the funding front, both of which are worth discussing and the first focus of this article. Secondly, I look forward to a potential catalys...

Gainers: Iterum Therapeutics (NASDAQ: ITRM ) +121% . More news on: Iterum Therapeutics plc, Pintec Technology Holdings Limited, PDS Biotechnology Corporation, Stocks on the move, Read more ...

Melinta Therapeutics ( MLNT )  files for Chapter 11 as part as an agreement with its senior credit facility lenders — Deerfield Private Design Fund III and Deerfield Private Design Fund IV — that would sell the company to the lenders. More news on: Melinta Therapeutics...

MORRISTOWN, N.J., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT) (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, tod...

Gainers:  Nortech Systems (NASDAQ: NSYS ) +98% . More news on: Nortech Systems Incorporated, FuelCell Energy, Inc., Cardlytics, Inc., Stocks on the move, Read more ...

Nano cap Melinta Therapeutics ( MLNT -44% ) slumps on more than double normal volume in reaction to its Q3 results . Highlights: More news on: Melinta Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Melinta Therapeutics ( MLNT ) Q3 results : Revenues: $15.9M (-53.4%). More news on: Melinta Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Melinta Therapeutics (NASDAQ: MLNT ): Q3 GAAP EPS of -$15.67 misses by $13.12 . Revenue of $15.87M (-53.4% Y/Y) misses by $0.43M . 10Q More news on: Melinta Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,

MORRISTOWN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it has filed its quarterly report on Fo...

Vocera Communications (NYSE: VCRA )  -27%  on Q3 earnings . More news on: Vocera Communications, Inc., Melinta Therapeutics, Inc., BeyondSpring Inc., Stocks on the move, Read more ...